Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nifedipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 6/20 | 0.97 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.97 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.97 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.97 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | SCN1A | P35498 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifedipine SCHEMBL29349595 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL1172946 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL3968 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL5694031 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076589 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27961697 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL8851397 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076587 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL8851402 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL9759614 | 0.95 | ADORA3 (0.93) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | claimed |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | NAVINTA LLC. | 2008-05-29 | — | — | US | claimed |
| US-20030124087-A1 | Anti-adhesion barrier | AMITIE CO. LTD. (KR) | 2003-07-03 | — | — | US | claimed |
| EP-1323436-A1 | Anti-adhesion barrier comprising carboxymethylcellulose and gellan gum | Amitie Co., Ltd. (KR) | 2003-07-02 | — | — | EP | claimed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | claimed |
| US-12433899-B2 | Therapeutics and method for treating osteoarthritis | CALOSYN PHARMA INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250134908-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250120937-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. | 2025-04-17 | — | — | US | disclosed |
| CN-112384223-B | Pharmaceutical composition containing poorly soluble basic agent | 中外制药株式会社 | 2024-08-27 | — | — | CN | disclosed |
| EP-4380688-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CaloSyn Pharma Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118159274-A | Syrup preparation | 中外制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-117205156-A | Pressure-sensitive multivesicular liposome for intervening in altitude pulmonary edema, and preparation method and application thereof | 徐州医科大学 | 2023-12-12 | — | — | CN | disclosed |
| EP-0793485-A4 | SUSTAINED-RELEASE DRUG DELIVERY EMPLOYING A POWDERED HYDROCOLLOID GUM OBTAINABLE FROM HIGHER PLANTS | CIBUS PHARMACEUTICAL INC (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0846465-A1 | REMEDY FOR ANXIETY NEUROSIS | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | disclosed |
| EP-0793485-A1 | SUSTAINED-RELEASE DRUG DELIVERY EMPLOYING A POWDERED HYDROCOLLOID GUM OBTAINABLE FROM HIGHER PLANTS | CIBUS PHARMACEUTICAL, INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016638-A1 | SUSTAINED-RELEASE DRUG DELIVERY EMPLOYING A POWDERED HYDROCOLLOID GUM OBTAINABLE FROM HIGHER PLANTS | CIBUS PHARMACEUTICAL, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| EP-0197504-B1 | PH-MEDIATED DRUG DELIVERY SYSTEM | MERCK & CO. INC. (US) | 1992-10-07 | — | — | EP | disclosed |
| US-4756710-A | pH-Mediated drug delivery system | MERCK & CO., INC. (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0197504-A2 | pH-mediated drug delivery system | MERCK & CO. INC. (US) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120937-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CA2, SLC16A1, ORAI1 | CACNA1C 30/4885CACNA1F 35/4885CACNA1D 34/4885 |
| US-12433899-B2 | Therapeutics and method for treating osteoarthritis | CA2, SLC16A1, ORAI1 | CACNA1C 29/4885CACNA1F 35/4885CACNA1D 33/4885 |
| US-20250134908-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CA2, SLC16A1, ORAI1 | CACNA1C 30/4885CACNA1F 35/4885CACNA1D 34/4885 |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | ADH1C, PRMT1, SCN1B | CACNA1C 11/4885CACNA1F 72/4885CACNA1D 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.